National patterns of warfarin use in atrial fibrillation

Archives of Internal Medicine

Volumn 156, Issue 22, 1996, Pages 2537-2541

  Stafford, Randall S ^a,b   Singer, Daniel E ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ANTICOAGULATION; ARTICLE; DRUG EFFICACY; EMBOLISM; HEART ATRIUM FIBRILLATION; MEDICAL PRACTICE; MEDICAL SPECIALIST; PHARMACOECONOMICS; PRESCRIPTION; PRIORITY JOURNAL; STROKE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG UTILIZATION; FEMALE; HEALTH CARE SURVEYS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OFFICE VISITS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; WARFARIN;

EID: 0029851556     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.22.2537     Document Type: Article

References (36)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med. 1987;147:1561-1564.
2. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
3. Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled, randomized trial of wartarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-179.
4. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
5. Connolly SJ, Laupacis A, Gent M, Roberts RS, Carins JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study, J Am Coll Cardiol. 1991;18:349-355.
6. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327:1406-1412.
7. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1256-1262.
8. Atrial Fibrillation Investigators. Atrial fibrillation: risk factors for embolization and efficacy of antithrombotic therapy. Arch Intern Med. 1994;154:1449-1457.
9. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with atrial fibrillation. JAMA. 1995;274:1839-1845.
10. Col NF, McLaughlin TJ, Soumerai SB, et al. The impact of clinical trials on the use of medications for acute myocardial infarction. Arch Intern Med. 1996; 156:54-60.
11. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM, for the CHS Collaborative Research Group. Prevalence ol atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236-241.
12. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994; 154:1945-1953.
13. National Center for Health Statistics. National Ambulatory Medical Care Survey: background and methodology, United States. Vital Health Stat 2. 1974; No. 61.
14. National Center for Health Statistics. Public Use Data Tape Documentation: 1980 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1982.
15. National Center for Health Statistics. Public Use Data Tape Documentation: 1981 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1984.
16. National Center for Health Statistics. Public Use Data Tape Documentation: 1985 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1987.
17. National Center for Health Statistics. Public Use Data Tape Documentation: 1989 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1992.
18. National Center for Health Statistics. Public Use Data Tape Documentation: 1990 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1992.
19. National Center for Health Statistics. Public Use Data Tape Documentation: 1991 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1993.
20. National Center for Health Statistics. Public Use Data Tape Documentation: 1992 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1994,
21. National Center for Health Statistics. Public Use Data Tape Documentation: 1993 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics, US Public Health Service; 1995.
22. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.
23. Langa KM, Sussman EJ. The effect of cost-containment policies on rates of coronary revascularization in California. N Engl J Med. 1993;329:1784-1789.
24. Wenneker MB, Epstein AM. Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts. JAMA. 1989;261:253-257.
25. Ayanian JZ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136-1142.
26. 26: Guadagnoli E, Hauptman PJ, Ayanian JZ, et al. Variation in the use of cardiac procedures after acute myocardial infarction. N Engl J Med. 1995;333:573-578.
27. Statistical Analysis System. SAS/STAT Users' Guide. Version 6. 4th ed. Cary, NC: SAS Institute lnc; 1990.
28. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons lnc; 1989.
29. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med. 1990; 322:863-868.
30. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients with warfarin. Ann Intern Med. 1994;120:892-902.
31. Singer DE. Randomized trials of warfarin for atrial fibrillation. N Engl J Med. 1992;27:1451-1453.
32. Fihn SD. Aiming for safe anticoagulation. N Engl J Med. 1995;333:54-55.
33. Matchar DB, McCrory DC, Barnett HJM, et al. American College of Physicians: guidelines for medical treatment for stroke prevention. Ann Intern Med. 1994; 121:54-55.
34. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108(suppl):352S-359S.
35. Singer DE. Anticoagulation to prevent stroke in atrial fibrillation. In: DiMarco JP, Prystowsky EN, eds. Atrial Arrhythmias: State of the Art. Armonk, NY: Futura Publishing Co; 1995:313-326.
36. Bussey HI, Rospond RM, Quandt CM, Clark GM. The safety and effectiveness of long-term warfarin therapy in an anticoagulation unit. Pharmacotherapy. 1989; 9:214-219.